New drug duo aims to control returning lymphoma

NCT ID NCT04989621

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs (orelabrutinib and rituximab) followed by maintenance orelabrutinib in 32 adults with relapsed or refractory follicular lymphoma. The goal is to see how well the treatment shrinks tumors and how long it keeps the cancer under control. Participants must have had prior treatment and be in adequate health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA RELAPSED AND REFRACTORY FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Guangdong General Hospital
RECRUITING

Guangzhou, Guangdong, 510000, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
NOT_YET_RECRUITING

Guangzhou, Guangdong, 51000, China
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
RECRUITING

Guangzhou, Guangdong, 51000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.